Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“Just in time for ASH25 MRD in Myeloma: all your questions answered! How to use MRD assessment in practice and research.
For a limited time get free access through this link.
The principles we discuss apply for all cancers. We discuss its use as
-Prognostic marker
-Regulatory endpoint
-Integral Biomarker to change therapy
-Marker of Cure.”
Title: Measurable residual disease assessment in multiple myeloma
Authors: Saurabh Zanwar, S. Vincent Rajkumar
More posts featuring Vincent S. Rajkumar on OncoDaily.
